Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila EB-AMDK 10
- Development stage
- Preclinical
- Lead developer
- Enterobiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Akkermansia muciniphila EB-AMDK 10 is a research-stage live biotherapeutic product (LBP) consisting of a specific strain of the Gram-negative, strictly anaerobic, mucin-degrading bacterium *Akkermansia muciniphila* isolated from the human gut. Developed by EverBiome, the strain is being investigated for its potential in treating obesity and metabolic dysregulation, including dyslipidemia and insulin resistance. EB-AMDK 10 demonstrates potent anti-lipogenic and anti-adipogenic activities, effectively suppressing intracellular lipid accumulation in adipocytes. In preclinical high-fat diet (HFD) mouse models, administration of the strain has been shown to prevent body weight gain, improve glucose homeostasis, restore gut barrier integrity, and inhibit low-grade intestinal inflammation. The strain's therapeutic effects are thought to be mediated through the modulation of the gut microbial population and the regulation of inflammatory pathways involving IL-6 and TLR4.
- Other names
- Akkermansia muciniphila strain EB-AMDK 10
Beyond the preview
Go deeper on Akkermansia muciniphila EB-AMDK 10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila EB-AMDK 10.